Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR70C1-ITNK
- Development stage
- Phase 1
- Lead developer
- Guangdong Zhaotai Cell Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR70C1-ITNK is an experimental cell therapy consisting of induced T-cell-derived Natural Killer (ITNK) cells engineered with a tandem chimeric antigen receptor (CAR) designed to simultaneously target CD70 and C-type lectin-like molecule-1 (CLL1/CLEC12A). Developed by Tongji Hospital, this therapy is specifically investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML). By utilizing a dual-targeting approach, the therapy aims to address the clonal heterogeneity of AML and prevent antigen escape, which is a common cause of relapse in single-target CAR therapies. The ITNK platform involves the use of NK-like cells derived from T cells, which are intended to combine the potent cytotoxicity of NK cells with the proliferative capacity of T cells, potentially offering an improved safety and efficacy profile in the treatment of myeloid malignancies.
- Other names
- CD70/CLL1 CAR-ITNKTandem CD70-CLL1 CAR-ITNK cellsCAR-ITNK Cells targeting CD70 and CLL1
02
Targets
CD70 (Cluster of Differentiation 70)CLEC12A
Beyond the preview
Go deeper on CAR70C1-ITNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR70C1-ITNK.